Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol
The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the...
Gespeichert in:
Veröffentlicht in: | Pharmacology, biochemistry and behavior biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 66 |
---|---|
container_issue | Pt A |
container_start_page | 59 |
container_title | Pharmacology, biochemistry and behavior |
container_volume | 139 |
creator | Jain, Nishant S. Tandi, Lakshyapati Verma, Lokesh |
description | The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation.
•Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR. |
doi_str_mv | 10.1016/j.pbb.2015.10.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751213242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305715300769</els_id><sourcerecordid>1751213242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</originalsourceid><addsrcrecordid>eNqNkUFP3DAQhS0EKsvSH8AF5cglW4_txEE9oVULlVbqpZwtx5mwXmXt1HYq8e9xlKVHxMmeN988jeYRcgN0AxTqb4fN2LYbRqHK9YZScUZW0EheViDlOVlReg8lp5W8JFcxHmgmWC2_kEtWi6pi8n5F_Na7FGw7Jetd4fsi7bEwmDU9FHsbkz5ah-HFmiJLLh5tjDNp3ULqpAccU25r1xUOp-BPNfY9mhRnz70e_IjBdn64Jhe9HiJ-Pb1r8vzzx5_tU7n7_fhr-7ArDW_qVDaMdrxveyMYmj5_GKe0bbHiNVCGvJUyKxyMFsC4AGFA5n7NkTZdLTq-JneL7xj83wljUnlzg8OgHfopKpAVMOBMsE-gvBENqyjPKCyoCT7GgL0agz3q8KqAqjkSdVA5EjVHMkv54Hnm9mQ_tUfs_k-8Z5CB7wuA-R7_LAYVjUVnsLMhX1B13n5g_wbzBJ1t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738482503</pqid></control><display><type>article</type><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</creator><creatorcontrib>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</creatorcontrib><description>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation.
•Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/j.pbb.2015.10.004</identifier><identifier>PMID: 26455279</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Animals ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - pharmacology ; Antipsychotic effects ; Avoidance Learning - drug effects ; Catalepsy ; Catalepsy - chemically induced ; Catalepsy - drug therapy ; Catalepsy - metabolism ; Chlorpheniramine - administration & dosage ; Chlorpheniramine - pharmacology ; Conditioned avoidance chamber ; Dose-Response Relationship, Drug ; Drug Synergism ; Haloperidol ; Haloperidol - administration & dosage ; Haloperidol - pharmacology ; Histamine ; Histamine - metabolism ; Histamine Agonists - administration & dosage ; Histamine Agonists - pharmacology ; Histidine - administration & dosage ; Histidine - pharmacology ; Infusions, Intraventricular ; Male ; Neuroleptics ; Piperidines - administration & dosage ; Piperidines - pharmacology ; Ranitidine - administration & dosage ; Ranitidine - pharmacology ; Rats ; Receptors, Histamine - metabolism ; Synaptic Transmission - drug effects]]></subject><ispartof>Pharmacology, biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</citedby><cites>FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091305715300769$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26455279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jain, Nishant S.</creatorcontrib><creatorcontrib>Tandi, Lakshyapati</creatorcontrib><creatorcontrib>Verma, Lokesh</creatorcontrib><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation.
•Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</description><subject>Animals</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic effects</subject><subject>Avoidance Learning - drug effects</subject><subject>Catalepsy</subject><subject>Catalepsy - chemically induced</subject><subject>Catalepsy - drug therapy</subject><subject>Catalepsy - metabolism</subject><subject>Chlorpheniramine - administration & dosage</subject><subject>Chlorpheniramine - pharmacology</subject><subject>Conditioned avoidance chamber</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Synergism</subject><subject>Haloperidol</subject><subject>Haloperidol - administration & dosage</subject><subject>Haloperidol - pharmacology</subject><subject>Histamine</subject><subject>Histamine - metabolism</subject><subject>Histamine Agonists - administration & dosage</subject><subject>Histamine Agonists - pharmacology</subject><subject>Histidine - administration & dosage</subject><subject>Histidine - pharmacology</subject><subject>Infusions, Intraventricular</subject><subject>Male</subject><subject>Neuroleptics</subject><subject>Piperidines - administration & dosage</subject><subject>Piperidines - pharmacology</subject><subject>Ranitidine - administration & dosage</subject><subject>Ranitidine - pharmacology</subject><subject>Rats</subject><subject>Receptors, Histamine - metabolism</subject><subject>Synaptic Transmission - drug effects</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFP3DAQhS0EKsvSH8AF5cglW4_txEE9oVULlVbqpZwtx5mwXmXt1HYq8e9xlKVHxMmeN988jeYRcgN0AxTqb4fN2LYbRqHK9YZScUZW0EheViDlOVlReg8lp5W8JFcxHmgmWC2_kEtWi6pi8n5F_Na7FGw7Jetd4fsi7bEwmDU9FHsbkz5ah-HFmiJLLh5tjDNp3ULqpAccU25r1xUOp-BPNfY9mhRnz70e_IjBdn64Jhe9HiJ-Pb1r8vzzx5_tU7n7_fhr-7ArDW_qVDaMdrxveyMYmj5_GKe0bbHiNVCGvJUyKxyMFsC4AGFA5n7NkTZdLTq-JneL7xj83wljUnlzg8OgHfopKpAVMOBMsE-gvBENqyjPKCyoCT7GgL0agz3q8KqAqjkSdVA5EjVHMkv54Hnm9mQ_tUfs_k-8Z5CB7wuA-R7_LAYVjUVnsLMhX1B13n5g_wbzBJ1t</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Jain, Nishant S.</creator><creator>Tandi, Lakshyapati</creator><creator>Verma, Lokesh</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QG</scope><scope>7TK</scope></search><sort><creationdate>201512</creationdate><title>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</title><author>Jain, Nishant S. ; Tandi, Lakshyapati ; Verma, Lokesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-820d3fbfc42ecffbf2300bbe536102e3b7723031ca4123414c170bb63e08d64d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic effects</topic><topic>Avoidance Learning - drug effects</topic><topic>Catalepsy</topic><topic>Catalepsy - chemically induced</topic><topic>Catalepsy - drug therapy</topic><topic>Catalepsy - metabolism</topic><topic>Chlorpheniramine - administration & dosage</topic><topic>Chlorpheniramine - pharmacology</topic><topic>Conditioned avoidance chamber</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Synergism</topic><topic>Haloperidol</topic><topic>Haloperidol - administration & dosage</topic><topic>Haloperidol - pharmacology</topic><topic>Histamine</topic><topic>Histamine - metabolism</topic><topic>Histamine Agonists - administration & dosage</topic><topic>Histamine Agonists - pharmacology</topic><topic>Histidine - administration & dosage</topic><topic>Histidine - pharmacology</topic><topic>Infusions, Intraventricular</topic><topic>Male</topic><topic>Neuroleptics</topic><topic>Piperidines - administration & dosage</topic><topic>Piperidines - pharmacology</topic><topic>Ranitidine - administration & dosage</topic><topic>Ranitidine - pharmacology</topic><topic>Rats</topic><topic>Receptors, Histamine - metabolism</topic><topic>Synaptic Transmission - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jain, Nishant S.</creatorcontrib><creatorcontrib>Tandi, Lakshyapati</creatorcontrib><creatorcontrib>Verma, Lokesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jain, Nishant S.</au><au>Tandi, Lakshyapati</au><au>Verma, Lokesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>2015-12</date><risdate>2015</risdate><volume>139</volume><issue>Pt A</issue><spage>59</spage><epage>66</epage><pages>59-66</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><abstract>The antipsychotic properties of haloperidol are primarily attributed to its ability to block dopamine D2 receptors. Histaminergic transmission modulates some of the behavioral effects of haloperidol. Hence, the present study investigated the contribution of central histaminergic transmission in the cataleptic and neuroleptic effect of haloperidol respectively, using bar test and conditioned avoidance response (CAR) in a two-way shuttle box. The studies revealed that haloperidol (0.50 or 1mg/kg, i.p.) exhibited cataleptic behavior and inhibited conditioned avoidance response (CAR) in the doses 0.25 or 0.50mg in rats. The rats, pretreated centrally (i.c.v.) with histamine precursor, l-histidine (1, 2.5μg) or histamine neuronal inducer (H3 receptor antagonist), thioperamide (20, 50μg/rat), showed an enhanced cataleptic effect with sub-maximal dose of haloperidol (0.5mg/kg, i.p.). Similarly, the neuroleptic effect of haloperidol (0.25mg/kg, i.p.) in CAR was also potentiated in the rats pretreated with l-histidine (2.5μg) or thioperamide (50μg/rat). Further, the cataleptic effect of haloperidol (1mg/kg, i.p.) was attenuated in rats pretreated with the H1 receptor antagonist, chlorpheniramine (60, 80μg/rat, i.c.v.) or H2 receptor antagonist, ranitidine (60μg/rat, i.c.v.). However, the neuroleptic effect of haloperidol (0.5mg/kg, i.p.) was completely reversed by pretreatment with ranitidine (60μg/rat, i.c.v.), and partially attenuated by chlorpheniramine (80μg/rat, i.c.v.). These findings suggest the possible involvement of histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol probably via H1 or H2 receptor stimulation.
•Contribution of histamine in the antipsychotic effect of haloperidol•Role of H1 or H2 receptor in the haloperidol induced catalepsy•Histamine stimulates H1 or H2 receptor to enhance haloperidol induced inhibition of CAR.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26455279</pmid><doi>10.1016/j.pbb.2015.10.004</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-3057 |
ispartof | Pharmacology, biochemistry and behavior, 2015-12, Vol.139 (Pt A), p.59-66 |
issn | 0091-3057 1873-5177 |
language | eng |
recordid | cdi_proquest_miscellaneous_1751213242 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Antipsychotic Agents - administration & dosage Antipsychotic Agents - pharmacology Antipsychotic effects Avoidance Learning - drug effects Catalepsy Catalepsy - chemically induced Catalepsy - drug therapy Catalepsy - metabolism Chlorpheniramine - administration & dosage Chlorpheniramine - pharmacology Conditioned avoidance chamber Dose-Response Relationship, Drug Drug Synergism Haloperidol Haloperidol - administration & dosage Haloperidol - pharmacology Histamine Histamine - metabolism Histamine Agonists - administration & dosage Histamine Agonists - pharmacology Histidine - administration & dosage Histidine - pharmacology Infusions, Intraventricular Male Neuroleptics Piperidines - administration & dosage Piperidines - pharmacology Ranitidine - administration & dosage Ranitidine - pharmacology Rats Receptors, Histamine - metabolism Synaptic Transmission - drug effects |
title | Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20the%20central%20histaminergic%20transmission%20in%20the%20cataleptic%20and%20neuroleptic%20effects%20of%20haloperidol&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Jain,%20Nishant%20S.&rft.date=2015-12&rft.volume=139&rft.issue=Pt%20A&rft.spage=59&rft.epage=66&rft.pages=59-66&rft.issn=0091-3057&rft.eissn=1873-5177&rft_id=info:doi/10.1016/j.pbb.2015.10.004&rft_dat=%3Cproquest_cross%3E1751213242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738482503&rft_id=info:pmid/26455279&rft_els_id=S0091305715300769&rfr_iscdi=true |